Doramapimod is an anticancer chemotherapeutic inhibitor of p38 MAPK and JNK that also displays some in vitro activity against anaplastic lymphoma kinase (ALK). Doramapimod is currently in clinical trials as a potential treatment for inflammatory diseases, exhibiting anti-inflammatory activity. In vitro, this compound inhibits expression of COX-2, MMP13, iNOS, and TNF-α and decreases release of prostaglandin E2 (PGE2), decreasing the overall inflammatory response.
| Cas No. | 2859873-48-4 |
|---|---|
| Purity | ≥98% |
| Formula | C31H37N5O3 |
| Formula Wt. | 527.66 |
| Chemical Name | 1-(3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(morpholin-4-yl)ethoxy)naphthalen-1-yl)urea |
| IUPAC Name | 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea |
| Synonym | 1-[2-(4-Methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; BIRB796 |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | D5868 Info Sheet PDF |
|---|
Hoogendijk AJ, Pinhanços SS, van der Poll T, et al. Intrapulmonary administration of a p38 mitogen activated protein kinase inhibitor partially prevents pulmonary inflammation. Immunobiology. 2013 Apr;218(4):435-42. PMID: 22727776.
af Gennäs GB, Mologni L, Ahmed S, et al. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. ChemMedChem. 2011 Sep 5;6(9):1680-92. PMID: 21721129.
Kuglstatter A, Ghate M, Tsing S, et al. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5217-20. PMID: 20655210.
Joos H, Albrecht W, Laufer S, et al. Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes. Br J Pharmacol. 2010 Jul;160(5):1252-62. PMID: 20590617.
Gruenbaum LM, Schwartz R, Woska JR Jr, et al. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem Pharmacol. 2009 Feb 1;77(3):422-32. PMID: 19027720.
Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem. 2005 May 20;280(20):19472-9. PMID: 15755732.
